# A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

> **NCT05200364** · PHASE1 · TERMINATED · sponsor: **Sutro Biopharma, Inc.** · enrollment: 58 (actual)

## Conditions studied

- Ovarian Cancer
- Ovarian Carcinoma
- Ovary Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** STRO-002
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05200364
- **Lead sponsor:** Sutro Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-22
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** Terminated Early
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05200364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05200364, "A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05200364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*